Monopar Therapeutics stock price prediction: Oversold CCI hints at possible rebound

Traders Union
All News
Stocks
Monopar rises 3.62% to $68.62 today

Highlights

Monopar Therapeutics will present Phase 3 FoCus baseline and ALXN1840 Molybdenum safety data at The Liver Meeting 2026.
Publication of new late-stage clinical data at a major conference gives insight into upcoming pipeline catalysts for MNPR stock.
Shares of Monopar Therapeutics trade below key moving averages and face immediate resistance at $70.1475, with a projected range of $64.2194 to $73.0206 and 65% probability of further downside.

Pipeline catalysts draw investor focus as data presentation nears

Monopar Therapeutics has announced it will present Phase 3 FoCus baseline data along with ALXN1840 Molybdenum safety data at AASLD - The Liver Meeting® 2026, according to Stockhouse. This disclosure highlights the company's advancing late-phase clinical development efforts, giving investors an early look at potential catalysts in Monopar's pipeline. The publication of new data at a notable scientific meeting may raise expectations around future trial results and contribute to demand for MNPR shares.

Momentum bias negative as MA resistance and indicators flag weakness

MNPR remains below its MA-20, MA-50, and MA-200, with the Ichimoku Kijun level at $70.1475 now acting as strong resistance. Key support is situated at $64.2194, while $73.0206 marks upper resistance for several sessions ahead. Both MACD and ADX maintain a sell bias, signaling continued weakness in trend momentum. RSI and Stochastic RSI oscillators are neutral, and CCI is oversold, hinting at possible selling exhaustion. Bull/Bear Power prints a negative −0.8994, and the Awesome Oscillator is showing a neutral stance.

Bearish tilt prevails as range-bound scenario dominates outlook

Looking ahead, MNPR is likely to consolidate within a projected range between $64.2194 and $73.0206 in the near term. The baseline scenario suggests continued sideways action, but a decisive move above $70.1475 would be required to trigger a bullish reversal. Conversely, a drop below $64.2194 would point to renewed selling pressure. Probability currently favors further downside with a 65% chance of decline, while the likelihood of an upside move stands at 35% under typical volatility conditions.

Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics as technically weak, with price stuck below key moving averages and major resistance at $70.1475. He notes that while the upcoming presentation of late-stage clinical data may boost sentiment, technical indicators point to a greater chance of further downside. The analyst cautions that real momentum will only return if the price decisively breaks above resistance. "Base case remains range-bound with a bearish tilt — no bullish setup unless $70.1475 is reclaimed," he says.

Earlier, analysts noted that Monopar Therapeutics was consolidating under persistent downside pressure amid unresolved technical uncertainty. This current assessment supports the earlier bearish outlook and highlights $70.1475 as a key resistance level that, if surpassed, could indicate a potential shift toward a bullish reversal.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.